First Quarter 2023 GAAP Revenue increased 7% to $219 million
First Quarter 2023 GAAP Net Income of $18 million
First Quarter 2023 GAAP Diluted Earnings Per Share of $0.51
First Quarter 2023 Adjusted Earnings Per Share of $0.74
First Quarter 2023 Adjusted EBITDA of $47 million
BEDFORD, Mass.–(BUSINESS WIRE)–Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the first quarter 2023.
Financial Highlights
Three Months Ended
(In millions, except per share amounts)
March 31,
April 1,
2023
2022
GAAP
Revenue
$
219.1
$
204.2
Operating Income
$
26.3
$
24.3
Consolidated Net Income
$
18.3
$
18.8
Diluted EPS
$
0.51
$
0.53
Non-GAAP*
Adjusted Operating Income
$
36.9
$
33.5
Adjusted Diluted EPS
$
0.74
$
0.73
Adjusted EBITDA
$
47.0
$
43.6
*Reconciliations of GAAP to non-GAAP financial measures, as well as definitions for the non-GAAP financial measures included in this press release and the reasons for their use, are presented below.
“Our first quarter results are a solid start to the year, thanks to the strong growth we are seeing in our medical end-markets,” said Matthijs Glastra, Chair and Chief Executive Officer of Novanta. “Our teams continue to execute well, reducing past-due orders to customers, while also maintaining overall customer backlog levels, resulting in strong organic growth, gross margins, and profit growth in the quarter.”
First Quarter
During the first quarter of 2023, Novanta generated GAAP revenue of $219.1 million, an increase of $14.9 million, or 7.3%, versus the first quarter of 2022. The Company’s acquisition activities resulted in an increase in revenue of $3.5 million, or 1.7%, compared to the first quarter of 2022. Changes in foreign currency exchange rates year over year adversely impacted our revenue by $5.8 million, or 2.8%, during the first quarter of 2023. Our year-over-year Organic Revenue Growth, which excludes the net impact of acquisitions and changes in foreign currency exchange rates, was an increase of 8.4% for the first quarter of 2023 (see “Organic Revenue Growth” in the non-GAAP reconciliations below).
In the first quarter of 2023, GAAP operating income was $26.3 million, compared to $24.3 million in the first quarter of 2022. GAAP net income was $18.3 million in the first quarter of 2023, compared to $18.8 million in the first quarter of 2022. GAAP diluted earnings per share (“EPS”) was $0.51 in the first quarter of 2023, compared to $0.53 in the first quarter of 2022.
Adjusted Diluted EPS was $0.74 in the first quarter of 2023, compared to $0.73 in the first quarter of 2022. The Company ended the first quarter of 2023 with 36.0 million diluted weighted average shares outstanding. Adjusted EBITDA was $47.0 million in the first quarter of 2023, compared to $43.6 million in the first quarter of 2022.
Operating cash flow for the first quarter of 2023 was $10.2 million, compared to $11.3 million for the first quarter of 2022. The Company completed the first quarter of 2023 with approximately $423.4 million of total debt and $82.7 million of total cash. Net Debt, as defined in the non-GAAP reconciliation below, was $345.3 million.
During the first quarter of 2023, the Company changed the names of its reportable segments from “Photonics” to “Precision Medicine and Manufacturing”, from “Vision” to “Medical Solutions”, and from “Precision Motion” to “Robotics and Automation”, respectively. The segment name changes did not result in any change to the compositions of the segments and therefore did not result in any change to historical results. The Company changed the names of these segments to better reflect the strategic focus of their technologies and applications.
Financial Guidance
“Strong growth in our medical end-markets drove our excellent first quarter financial performance,” said Matthijs Glastra. “We are on track with our previously issued full year 2023 guidance, and expect to drive a more linear first half financial performance. In addition, demand continues to build beyond 2023 from the new products launching in our medical and industrial applications, which are on track to launch later in 2023 and in 2024.”
For the second quarter of 2023, the Company expects GAAP revenue of approximately $222 million to $225 million. The Company expects Adjusted EBITDA to be in the range of $47 million to $49 million and Adjusted Diluted EPS to be in the range of $0.70 to $0.74. The Company’s guidance assumes no significant changes in foreign exchange rates.
Novanta provides earnings guidance on a non-GAAP basis and does not provide earnings guidance on a GAAP basis, with the exception of GAAP revenue guidance. A reconciliation of the Company’s forward-looking Adjusted Gross Profit Margin, Adjusted EBITDA and Adjusted Diluted EPS guidance to the most directly comparable GAAP financial measures is not provided because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including future changes in the fair value of contingent considerations; significant discrete income tax expenses (benefits); divestitures and related expenses; acquisitions and related expenses; impact of purchase price allocations for recently completed acquisitions; gains and losses from sale of real estate assets; costs related to product line closures; intangible asset impairment charges and related asset write-offs; future restructuring expenses; foreign exchange gains/(losses); benefits or expenses associated with the completion of tax audits; and other charges reflected in the Company’s reconciliation of historical non-GAAP financial measures, the amounts of which, based on past experience, could be material. For additional information regarding Novanta’s non-GAAP financial measures, see “Use of Non-GAAP Financial Measures” below.
Conference Call Information
The Company will host a conference call on Tuesday, May 9, 2023 at 10:00 a.m. ET to discuss these results and to provide a business update. To access the call, please dial (888) 346-3959 prior to the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company’s website at www.novanta.com.
A replay of the audio webcast will be available approximately three hours after the conclusion of the call in the Investor Relations section of the Company’s website at www.novanta.com. The replay will remain available until Monday, July 3, 2023.
Use of Non-GAAP Financial Measures
The non-GAAP financial measures used in this press release are Organic Revenue Growth, Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating Income and Operating Margin, Adjusted Income before Income Taxes, Adjusted Income Tax Provision/(Benefit) and Effective Tax Rate, Adjusted Net Income, Adjusted Diluted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Free Cash Flow as a Percentage of Net Income, and Net Debt.
The Company believes that these non-GAAP financial measures provide useful and supplementary information to investors regarding the operating performance of the Company. It is management’s belief that these non-GAAP financial measures would be particularly useful to investors because of the significant changes that have occurred outside of the Company’s day-to-day business in accordance with the execution of the Company’s strategy. This strategy includes streamlining the Company’s existing operations through site and functional consolidations, strategic divestitures and product line closures, expanding the Company’s business through significant internal investments, and broadening the Company’s product and service offerings through acquisition of innovative and complementary technologies and solutions. The financial impact of certain elements of these activities, particularly acquisitions, divestitures, and site and functional restructurings, is often large relative to the Company’s overall financial performance and can adversely affect the comparability of its operating results and investors’ ability to analyze the business from period to period.
The Company’s Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Margin are used by management to evaluate operating performance, communicate financial results to the Board of Directors, benchmark results against historical performance and the performance of peers, and evaluate investment opportunities, including acquisitions and divestitures. In addition, Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Margins are used to determine bonus payments for senior management and employees. The Company also uses Adjusted Diluted EPS and Adjusted EBITDA as performance targets for certain performance-based restricted stock units issued to certain executives. Accordingly, the Company believes that these non-GAAP financial measures provide greater transparency and insight into management’s method of analysis.
Non-GAAP financial measures should not be considered as substitutes for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on the Company’s reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company’s financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial measures. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.
Safe Harbor and Forward-Looking Information
Certain statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in this news release that do not relate to matters of historical fact should be considered forward-looking statements, and are generally identified by words such as “expect,” “intend,” “anticipate,” “estimate,” “believe,” “future,” “could,” “should,” “plan,” “aim,” and other similar expressions. These forward-looking statements include, but are not limited to, statements regarding anticipated financial performance and financial position, including our financial outlook for the second quarter of 2023; expectations for our end markets and market position; expectations regarding our ability to navigate difficult macroeconomic conditions; our ability to deliver sustained long-term shareholder value; expectations regarding our backlog and demand in our medical and advanced industrial end-markets; and other statements that are not historical facts.
These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, but not limited to, the following: economic and political conditions and the effects of these conditions on our customers’ businesses, capital expenditures and level of business activities; risks associated with epidemics or pandemics, such as the COVID-19 pandemic and other events outside our control; our dependence upon our ability to respond to fluctuations in product demand; our ability to continually innovate, introduce new products timely, and successfully commercialize our innovations; failure to introduce new products in a timely manner; customer order timing and other similar factors may cause fluctuations in our operating results; cyberattacks, disruptions or other breaches in security of our and our third-party providers’ information technology systems; our failure to comply with data privacy regulations; changes in interest rates, credit ratings or foreign currency exchange rates; risks associated with our operations in foreign countries; our increased use of outsourcing in foreign countries; risks associated with increased outsourcing of components manufacturing; our exposure to increased tariffs, trade restrictions or taxes on our products; the continuing impact of “Brexit”; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our business; our ability to attract and retain key personnel; our restructuring and realignment activities and disruptions to our operations as a result of consolidation of our operations; product defects or problems integrating our products with other vendors’ products; disruptions in the supply of certain key components or other goods from our suppliers; our failure to accurately forecast component and raw material requirements leading to excess inventories or delays in the delivery of our products; production difficulties and product delivery delays or disruptions; our exposure to medical device regulations, which may impede or hinder the approval or sale of our products and, in some cases, may ultimately result in an inability to obtain approval of certain products or may result in the recall or seizure of previously approved products; potential penalties for violating foreign, U.S. federal, and state healthcare laws and regulations; impact of healthcare industry cost containment and healthcare reform measures; changes in governmental regulations affecting our business or products; our failure to implement new information technology systems and software successfully; our failure to realize the full value of our intangible assets; increasing scrutiny and changing expectations from investors, customers, and governments with respect to Environmental, Social and Governance policies and practices; our reliance on original equipment manufacturer customers; being subject to U.S. federal income taxation even though we are a non-U.S. corporation; changes in tax laws, and fluctuations in our effective tax rates; our exposure to the credit risk of some of our customers and in weakened markets; any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance our existing indebtedness, which may not be available on acceptable terms or at all; our existing indebtedness limiting our ability to engage in certain activities; volatility in the market price for our common shares; and our failure to maintain appropriate internal controls in the future.
Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition are discussed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as updated by our subsequent filings with the Securities and Exchange Commission. Such statements are based on the Company’s beliefs and assumptions and on information currently available to the Company. The Company disclaims any obligation to publicly update or revise any such forward-looking statements as a result of developments occurring after the date of this document except as required by law.
About Novanta
Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine and manufacturing, medical solutions, and robotics and automation with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers’ demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation and customer success. Novanta’s common shares are quoted on Nasdaq under the ticker symbol “NOVT.”
More information about Novanta is available on the Company’s website at www.novanta.com. For additional information, please contact Novanta Investor Relations at (781) 266-5137 or [email protected].
NOVANTA INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands of U.S. dollars or shares, except per share amounts)
(Unaudited)
Three Months Ended
March 31,
April 1,
2023
2022
Revenue
$
219,126
$
204,216
Cost of revenue
121,498
113,940
Gross profit
97,628
90,276
Operating expenses:
Research and development and engineering
22,828
20,929
Selling, general and administrative
40,923
39,352
Amortization of purchased intangible assets
5,089
7,342
Restructuring, acquisition, and related costs
2,476
(1,630
)
Total operating expenses
71,316
65,993
Operating income
26,312
24,283
Interest income (expense), net
(6,332
)
(3,109
)
Foreign exchange transaction gains (losses), net
(77
)
69
Other income (expense), net
(166
)
(545
)
Income before income taxes
19,737
20,698
Income tax provision (benefit)
1,472
1,878
Consolidated net income
$
18,265
$
18,820
Earnings per common share:
Basic
$
0.51
$
0.53
Diluted
$
0.51
$
0.53
Weighted average common shares outstanding—basic
35,810
35,538
Weighted average common shares outstanding—diluted
35,999
35,781
NOVANTA INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands of U.S. dollars)
(Unaudited)
March 31,
December 31,
2023
2022
ASSETS
Current Assets
Cash and cash equivalents
$
82,676
$
100,105
Accounts receivable, net
141,472
137,697
Inventories
166,671
167,997
Prepaid expenses and other current assets
13,974
14,720
Total current assets
404,793
420,519
Property, plant and equipment, net
103,967
103,186
Operating lease assets
41,964
43,317
Intangible assets, net
168,828
175,766
Goodwill
482,520
478,897
Other assets
23,743
19,527
Total assets
$
1,225,815
$
1,241,212
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Current portion of long-term debt
$
4,904
$
4,800
Accounts payable
66,009
75,225
Accrued expenses and other current liabilities
71,440
84,497
Total current liabilities
142,353
164,522
Long-term debt
418,535
430,662
Operating lease liabilities
39,578
40,808
Other long-term liabilities
27,332
27,634
Total liabilities
627,798
663,626
Stockholders’ Equity:
Total stockholders’ equity
598,017
577,586
Total liabilities and stockholders’ equity
$
1,225,815
$
1,241,212
NOVANTA INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands of U.S. dollars)
(Unaudited)
Three Months Ended
March 31,
April 1,
2023
2022
Cash flows from operating activities:
Consolidated net income
$
18,265
$
18,820
Adjustments to reconcile consolidated net income to net cash provided by operating activities:
Depreciation and amortization
11,731
14,044
Share-based compensation
6,466
6,774
Deferred income taxes
(3,695
)
(5,140
)
Other
2,587
(1,014
)
Changes in assets and liabilities which (used)/provided cash, excluding effects from business acquisitions:
Accounts receivable
(2,920
)
(8,949
)
Inventories
52
(14,928
)
Other operating assets and liabilities
(22,241
)
1,740
Net cash provided by (used in) operating activities
10,245
11,347
Cash flows from investing activities:
Purchases of property, plant and equipment
(3,620
)
(6,308
)
Payment of contingent consideration related to acquisition of technology assets
—
(1,470
)
Other investing activities
—
957
Net cash provided by (used in) investing activities
(3,620
)
(6,821
)
Cash flows from financing activities:
Repayments under term loan and revolving credit facilities
(15,309
)
(11,640
)
Payments of debt issuance costs
—
(2,133
)
Payments of withholding taxes from share-based awards
(9,601
)
(7,733
)
Other financing activities
(156
)
(523
)
Net cash provided by (used in) financing activities
(25,066
)
(22,029
)
Effect of exchange rates on cash and cash equivalents
1,012
(1,085
)
Increase (decrease) in cash and cash equivalents
(17,429
)
(18,588
)
Cash and cash equivalents, beginning of period
100,105
117,393
Cash and cash equivalents, end of period
$
82,676
$
98,805
NOVANTA INC.
Revenue by Reportable Segment
(In thousands of U.S. dollars)
(Unaudited)
Three Months Ended
March 31,
April 1,
2023
2022
Revenue
Precision Medicine and Manufacturing
$
69,528
$
62,782
Medical Solutions
77,640
62,050
Robotics and Automation
71,958
79,384
Total
$
219,126
$
204,216
NOVANTA INC.
Reconciliation of GAAP to Non-GAAP Financial Measures
(In thousands of U.S. dollars)
(Unaudited)
Adjusted Gross Profit and Adjusted Gross Profit Margin by Reportable Segment (Non-GAAP):
Three Months Ended
March 31,
April 1,
2023
2022
Precision Medicine and Manufacturing
Gross Profit (GAAP)
$
34,333
$
28,387
Gross Profit Margin (GAAP)
49.4
%
45.2
%
Amortization of intangible assets
570
664
Acquisition fair value adjustments
—
—
Adjusted Gross Profit (Non-GAAP)
$
34,903
$
29,051
Adjusted Gross Profit Margin (Non-GAAP)
50.2
%
46.3
%
Medical Solutions
Gross Profit (GAAP)
$
31,886
$
25,230
Gross Profit Margin (GAAP)
41.1
%
40.7
%
Amortization of intangible assets
1,064
1,257
Acquisition fair value adjustments
—
—
Adjusted Gross Profit (Non-GAAP)
$
32,950
$
26,487
Adjusted Gross Profit Margin (Non-GAAP)
42.4
%
42.7
%
Robotics and Automation
Gross Profit (GAAP)
$
32,815
$
38,150
Gross Profit Margin (GAAP)
45.6
%
48.1
%
Amortization of intangible assets
1,388
1,502
Acquisition fair value adjustments
—
—
Adjusted Gross Profit (Non-GAAP)
$
34,203
$
39,652
Adjusted Gross Profit Margin (Non-GAAP)
47.5
%
49.9
%
Unallocated Corporate and Shared Services
Gross Profit (GAAP)
$
(1,406
)
$
(1,491
)
Amortization of intangible assets
—
—
Employee COVID-19 testing costs
—
125
Adjusted Gross Profit (Non-GAAP)
$
(1,406
)
$
(1,366
)
Novanta Inc.
Gross Profit (GAAP)
$
97,628
$
90,276
Gross Profit Margin (GAAP)
44.6
%
44.2
%
Amortization of intangible assets
3,022
3,423
Acquisition fair value adjustments
—
—
Employee COVID-19 testing costs
—
125
Adjusted Gross Profit (Non-GAAP)
$
100,650
$
93,824
Adjusted Gross Profit Margin (Non-GAAP)
45.9
%
45.9
%
NOVANTA INC.
Reconciliation of GAAP to Non-GAAP Financial Measures
(Amounts in thousands except per share amounts)
(Unaudited)
Adjusted Operating Income and Adjusted Diluted EPS (Non-GAAP):
Three Months Ended March 31, 2023
Operating Income
Operating Margin
Income Before Income Taxes
Income Tax Provision / (Benefit)
Effective Tax Rate
Consolidated Net Income
Diluted EPS
GAAP results
$
26,312
12.0
%
$
19,737
$
1,472
7.5
%
$
18,265
$
0.51
Non-GAAP Adjustments:
Amortization of intangible assets
8,111
3.7
%
8,111
Restructuring costs
2,471
1.1
%
2,471
Acquisition and related costs
5
0.0
%
5
Foreign exchange transaction (gains) losses, net
77
Tax effect on non-GAAP adjustments
2,130
Non-GAAP tax adjustments
(3
)
Total non-GAAP adjustments
10,587
4.8
%
10,664
2,127
8,537
0.23
Adjusted results (Non-GAAP)
$
36,899
16.8
%
$
30,401
$
3,599
11.8
%
$
26,802
$
0.74
Weighted average shares outstanding – Diluted
35,999
Contacts
Novanta Inc.
Investor Relations Contact:
Ray Nash
(781) 266-5137
